Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Seroma 4 Melanoma 3 Postoperative Complications 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Stomach Neoplasms 1 Lymphoma, Follicular 1 Lymphocele 1 Lymphedema 1 Hemorrhage 1 Carcinoma, Squamous Cell 1 Bone Neoplasms 1 Anastomotic Leak 1

Interventions

Ibandronic Acid 8 Gemcitabine 8 Doxorubicin 6 Cyclophosphamide 6 Zoledronic Acid 5 Radiation 4 Nivolumab 4 Irinotecan 4 pembrolizumab 3 Vincristine 3 Temozolomide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Docetaxel 3 Denosumab 3 Cisplatin 3 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3 regorafenib 2 pegfilgrastim 2 Tranexamic Acid 2 Trabectedin 2 Surveys and Questionnaires 2 Sunitinib 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiosurgery 2 Quality of Life 2 Proton Therapy 2 Observation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Bone Neoplasms × Fibrin Tissue Adhesive × Clear all

NCT02153593 2016-09-20

TRANEXTUM

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 3 Terminated

Bone Neoplasms, Hemorrhage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡